These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22820651)

  • 1. Shaping our future.
    Chiti A
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1371-2. PubMed ID: 22820651
    [No Abstract]   [Full Text] [Related]  

  • 2. The future of nuclear medicine.
    Ell PJ; Hoejgaard L; Becker W
    Lancet; 2002 Feb; 359(9306):629-30. PubMed ID: 11867148
    [No Abstract]   [Full Text] [Related]  

  • 3. Future of nuclear medicine, part 3: assessment of the U.S. therapeutic radiopharmaceuticals market (2001-2020).
    J Nucl Med; 1998 Jul; 39(7):14N, 17N-18N, 20N-22N, 25N, 27N. PubMed ID: 9669377
    [No Abstract]   [Full Text] [Related]  

  • 4. Molybdenum supplies and nuclear medicine services.
    Perkins AC; Vivian G
    Nucl Med Commun; 2009 Sep; 30(9):657-9. PubMed ID: 19644241
    [No Abstract]   [Full Text] [Related]  

  • 5. Future of nuclear medicine, part 2: assessment of the U.S. diagnostic radio-pharmaceuticals market (2001-2020).
    J Nucl Med; 1998 Mar; 39(3):20N, 22N-25N. PubMed ID: 9529277
    [No Abstract]   [Full Text] [Related]  

  • 6. Policy and regulatory news from SNM, Capitol Hill, and beyond.
    Cannon H
    J Nucl Med; 2007 Jul; 48(7):34N. PubMed ID: 17607036
    [No Abstract]   [Full Text] [Related]  

  • 7. Public affairs update. NM APC Task Force and proposed HOPPS changes.
    J Nucl Med; 2001 Nov; 42(11):16N, 21N. PubMed ID: 11710336
    [No Abstract]   [Full Text] [Related]  

  • 8. Future of nuclear medicine, part 1: marketing research forecasts.
    J Nucl Med; 1998 Feb; 39(2):27N-30N. PubMed ID: 9476920
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cost-effectiveness of radiopharmaceuticals in the hospital].
    Fotopoulos A
    Hell J Nucl Med; 2005; 8(1):29. PubMed ID: 15886749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Return of the radionuclide shortage.
    Knight N
    J Nucl Med; 2009 Jul; 50(7):13N-14N. PubMed ID: 19652219
    [No Abstract]   [Full Text] [Related]  

  • 11. Costs versus charges.
    Makler PT
    J Nucl Med; 1998 Dec; 39(12):2194. PubMed ID: 9867171
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing the unmanageable.
    Atcher RW
    Lancet Oncol; 2009 Aug; 10(8):745-6. PubMed ID: 19647197
    [No Abstract]   [Full Text] [Related]  

  • 13. [GMP production.Shaping the future].
    Wester HJ
    Nuklearmedizin; 2012; 51(1):N1-4. PubMed ID: 22448395
    [No Abstract]   [Full Text] [Related]  

  • 14. CPT code recommendations for nuclear medicine therapy.
    McKusick KA; Wilson M
    J Nucl Med; 2002 Jul; 43(7):27N-28N. PubMed ID: 12109487
    [No Abstract]   [Full Text] [Related]  

  • 15. Understanding patient needs: congressmen aid nuclear medicine.
    Kotz D
    J Nucl Med; 1998 Nov; 39(11):16N, 21N-22N, 30N. PubMed ID: 9829563
    [No Abstract]   [Full Text] [Related]  

  • 16. 2003 HOPPS includes cuts for nuclear medicine.
    J Nucl Med; 2002 Sep; 43(9):33N. PubMed ID: 12227351
    [No Abstract]   [Full Text] [Related]  

  • 17. Economics of nuclear medicine. Introduction.
    Gambhir SS
    Q J Nucl Med; 2000 Jun; 44(2):103-4. PubMed ID: 10967620
    [No Abstract]   [Full Text] [Related]  

  • 18. A defining moment: Nuclear medicine, molecular imaging, SNM.
    Sandler MP
    J Nucl Med; 2006 Jul; 47(7):36N, 37N. PubMed ID: 16871699
    [No Abstract]   [Full Text] [Related]  

  • 19. Nuclear Medicine and Wall Street: An Evolving Relationship.
    Sherman M; Levine R
    J Nucl Med; 2019 Sep; 60(Suppl 2):20S-24S. PubMed ID: 31481585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guest editorial: the future of nuclear medicine in the management of CNS diseases.
    Mountz JM
    Semin Nucl Med; 2012 Nov; 42(6):354-5. PubMed ID: 23026358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.